MetLife Investment Management LLC Reduces Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

MetLife Investment Management LLC lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,967 shares of the biopharmaceutical company’s stock after selling 708 shares during the quarter. MetLife Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $29,400,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Rakuten Securities Inc. raised its holdings in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $26,000. Sachetta LLC grew its position in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the last quarter. Lynx Investment Advisory acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $33,000. Finally, Family Firm Inc. bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $753.03 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $735.95 and a 12 month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market cap of $82.75 billion, a PE ratio of 18.63, a price-to-earnings-growth ratio of 2.89 and a beta of 0.15. The business has a fifty day simple moving average of $929.13 and a 200-day simple moving average of $1,024.43.

Analyst Ratings Changes

Several research firms have commented on REGN. Oppenheimer decreased their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price on the stock. Evercore ISI cut their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Finally, StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $1,099.55.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.